FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

Autor: Birgit I. Lissenberg-Witte, Karl Ulrich Petry, Frederique J Vink, Renske D.M. Steenbergen, Marta del Pino, Anja Oštrbenk, Helle Pedersen, Chris J.L.M. Meijer, Albertus T. Hesselink, Daniëlle A M Heideman, Kate Cuschieri, Wim Quint, Silvia de Sanjosé, Nienke E. van Trommel, M. Torres, Arno Floore, Gary M. Clifford, Mario Poljak, Elia Alcañiz Boada, Beate Rothe, Jesper Bonde, Maaike C G Bleeker
Přispěvatelé: Pathology, CCA - Cancer biology and immunology, AII - Infectious diseases, Epidemiology and Data Science, APH - Methodology
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: International Journal of Cancer, 147(4), 1215-1221. Wiley-Liss Inc.
Vink, F J, Meijer, C J L M, Clifford, G M, Poljak, M, Oštrbenk, A, Petry, K U, Rothe, B, Bonde, J, Pedersen, H, de Sanjosé, S, Torres, M, Del Pino, M, Quint, W G V, Cuschieri, K, Alcañiz Boada, E, van Trommel, N E, Lissenberg-Witte, B I, Floore, A N, Hesselink, A T, Steenbergen, R D M, Bleeker, M C G & Heideman, D A M 2020, ' FAM19A4/miR124-2 methylation in invasive cervical cancer : A retrospective cross-sectional worldwide study ', International Journal of Cancer, vol. 147, no. 4, pp. 1215-1221 . https://doi.org/10.1002/ijc.32614
International Journal of Cancer
ISSN: 0020-7136
Popis: Widespread adoption of primary human papillomavirus (HPV)‐based screening has encouraged the search for a triage test which retains high sensitivity for the detection of cervical cancer and precancer, but increases specificity to avoid overtreatment. Methylation analysis of FAM19A4 and miR124‐2 genes has shown promise for the triage of high‐risk (hr) HPV‐positive women. In our study, we assessed the consistency of FAM19A4/miR124‐2 methylation analysis in the detection of cervical cancer in a series of 519 invasive cervical carcinomas (n = 314 cervical scrapes, n = 205 tissue specimens) from over 25 countries, using a quantitative methylation‐specific PCR (qMSP)‐based assay (QIAsure Methylation Test®). Positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were calculated. In total, 510 of the 519 cervical carcinomas (98.3%; 95% CI: 96.7–99.2) tested FAM19A4/miR124‐2 methylation‐positive. Test positivity was consistent across the different subgroups based on cervical cancer histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. In conclusion, FAM19A4/miR124‐2 methylation analysis detects nearly all cervical carcinomas, including rare histotypes and hrHPV‐negative carcinomas. These results indicate that a negative FAM19A4/miR124‐2 methylation assay result is likely to rule out the presence of cervical cancer.
What's new? Methylation analysis of host cell genes is a promising strategy for the triage of women who test positive for high‐risk human papillomavirus (hrHPV). Its ability to consistently detect cervical cancer, however, warrants further evaluation. In this retrospective cross‐sectional study of more than 500 cervical cancer cases worldwide, methylation analysis using FAM19A4 and miR124‐2 genes successfully detected the vast majority of cervical carcinomas. Detection by FAM19A4/miR124‐2 methylation analysis was consistent regardless of multiple factors, including hrHPV status and genotype, cancer histotype, sample type, and geographical region. The findings suggest that a negative FAM19A4/miR124‐2 methylation test result is likely to rule out cervical cancer.
Databáze: OpenAIRE
Externí odkaz: